Earlier in the thread, there was talk about glioma, a brain tumor often lacking cures. This study includes several different brain tumors, one brain metastasis, and meningioma, which is a benign tumor.
And medulloblastoma, the most common malignant brain tumor in children.
Maija’s review of Bex’s treatment possibilities https://www.tandfonline.com/doi/10.1080/1750743X.2026.2617035?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed#d1e818 examined Clever concentration in various cancers and the absence of inflammatory cells, indicating a cold immune environment. One of the glioomas studied was found to be a suitable target for Bex.
This appears to be a conference abstract in the esteemed publication Journal for ImmunoTherapy of Cancer.
Apparently from here: https://www.itoc-conference.eu/
Patient samples were studied, and results supporting previous observations were obtained again:
“These responders showed low IFN signaling at baseline, while bexmarilimab induced proinflammatory immune responses. This suggested enhanced antigen presentation, stimulation of IFN-gamma, IFN-alpha, and TNF-alpha signaling, and suppression of M2-macrophage-typical features.”
In this work, the blood-brain barrier (BBB) was “bypassed”. Now we should consider how Bex would enter the brain. Is it a cancer-weakened blood-brain barrier? That’s possible in aggressive tumors. Artificial opening, radiation therapy? On the other hand, pembro, which is a similar antibody to Bex, shows some effect on melanoma brain metastases https://pubmed.ncbi.nlm.nih.gov/30407895/?utm_source, but this might involve activated T-cells that can enter the brain. This would require a primary tumor that has metastasized.
If these brain tumor endeavors continue, even more effort should be put into developing a blood-brain barrier-penetrating anti-Clever small molecule.
This is a very early stage; due to the small number of patients per diagnosis, sub-analyses cannot be performed. It adds more rows to the “dreams” Excel sheet and strengthens the case that it doesn’t matter what the cancer is; it seems to work preliminarily in various cancers, regardless of their name, as long as Clever-1 is in the environment and immunity is cold. That has been the assumption for the past few years. Hats off again, even if my hair is thinning here.